Abstract | BACKGROUND: OBJECTIVE: DESIGN AND METHODS: RESULTS:
GRalpha and GR-P mRNA constituted 87 +/- 8% and 13 +/- 2%, respectively, of total GR mRNA in liver. GRbeta mRNA could only be amplified in five liver samples. All variants were present in most muscle samples (alpha = 96 +/- 11%, P = 3.9 +/- 0.4%, beta = 0.010 +/- 0.002%). GR expression was not associated with insulin therapy. A strong positive relationship was observed between the different GR variants in both liver and muscle (P < 0.001 for all). Serum cortisol levels were negatively associated with liver GRalpha and muscle GR-P expression (P < 0.05). mRNA expression of both liver GRalpha and GR-P, but not muscle GR, was substantially lower in patients who had received exogenous glucocorticoids (P < 0.01). CONCLUSION:
|
Authors | R P Peeters, A Hagendorf, I Vanhorebeek, T J Visser, W Klootwijk, D Mesotten, P J Wouters, J W Koper, F H de Jong, R A Feelders, S W J Lamberts, G Van den Berghe |
Journal | Clinical endocrinology
(Clin Endocrinol (Oxf))
Vol. 71
Issue 1
Pg. 145-53
(Jul 2009)
ISSN: 1365-2265 [Electronic] England |
PMID | 19178514
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Glucocorticoids
- Insulin
- Receptors, Glucocorticoid
|
Topics |
- Aged
- Aged, 80 and over
- Alternative Splicing
- Critical Illness
(therapy)
- Female
- Gene Expression
- Glucocorticoids
(therapeutic use)
- Humans
- Insulin
(therapeutic use)
- Intensive Care Units
- Liver
(metabolism)
- Male
- Middle Aged
- Muscles
(metabolism)
- Receptors, Glucocorticoid
(genetics, metabolism)
|